Compare PCRX & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | MFA |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | N/A |
| Metric | PCRX | MFA |
|---|---|---|
| Price | $23.50 | $9.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $30.25 | $11.05 |
| AVG Volume (30 Days) | 516.5K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.16% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | $10.02 |
| P/E Ratio | $336.29 | ★ $7.75 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $8.78 |
| 52 Week High | $27.64 | $10.57 |
| Indicator | PCRX | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 42.52 |
| Support Level | $22.13 | $9.38 |
| Resistance Level | $24.20 | $9.79 |
| Average True Range (ATR) | 1.02 | 0.20 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 42.93 | 20.94 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.